aTyr Pharma (ATYR) Stock Price
aTyr Pharma Price
aTyr Pharma (ATYR) Stock | ISIN US0021202025 | WKN A2PM86. The current aTyr Pharma stock price is 0.47 USD (2026). Revenue is 18.49 M USD. Net income is -62.83 M USD. The P/E ratio is -0.56. Market capitalization is 46.06 M USD. aTyr Pharma operates in the Health sector.
aTyr Pharma stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of aTyr Pharma over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how aTyr Pharma stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing aTyr Pharma's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | aTyr Pharma Price |
|---|
aTyr Pharma Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
aTyr Pharma Income Statement, Balance Sheet, Cash Flow Statement
| REVENUE (M USD) |
|---|
| REVENUE GROWTH (%) |
| GROSS MARGIN (%) |
| GROSS INCOME (M USD) |
| NET INCOME (M USD) |
| NET INCOME GROWTH (%) |
| SHARES (M) |
| DOCUMENTS |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales aTyr Pharma generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue aTyr Pharma retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare aTyr Pharma's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares aTyr Pharma has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against aTyr Pharma's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
aTyr Pharma stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
aTyr Pharma Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
aTyr Pharma business model & stock analysis
aTyr Pharma SWOT Analysis
Strengths
1. Unique pipeline: aTyr Pharma Inc has a strong portfolio of innovative therapeutics focusing on rare genetic diseases. The company's products have the potential to address unmet medical needs.
2. Patented technology: aTyr's proprietary Physiocrine biology platform enables the discovery and development of protein-based therapeutics. This cutting-edge technology provides the company with a competitive advantage.
3. Strong research and development capabilities: aTyr Pharma has a dedicated team of scientists and experts in biotechnology, ensuring the continuous development of novel drug candidates.
Weaknesses
1. Limited market presence: aTyr Pharma Inc is a relatively small and emerging player in the pharmaceutical industry. This lack of market recognition may pose challenges in gaining widespread adoption of their products.
2. Dependence on key partnerships: The company relies heavily on collaborations with research institutions and pharmaceutical companies for funding and expertise. Any disruption in these partnerships could impact aTyr's operations.
3. High research and development costs: Developing new drugs and conducting clinical trials can be expensive. As a smaller company, aTyr Pharma may face financial constraints in advancing its pipeline at the desired pace.
Opportunities
1. Growing demand for rare disease treatments: The pharmaceutical industry is increasingly focused on developing therapies for rare genetic disorders, presenting aTyr with opportunities to capture a niche market and address significant unmet medical needs.
2. Strategic collaborations: Forming partnerships with larger pharmaceutical companies can provide aTyr with access to additional resources, funding, and expertise necessary for accelerated research and development.
3. Expansion into global markets: As aTyr Pharma's products gain regulatory approvals, there is potential for international expansion, tapping into markets beyond the United States and increasing revenue streams.
Threats
1. Competitive landscape: The pharmaceutical industry is highly competitive, with numerous established players and emerging biotech companies. aTyr Pharma faces the risk of larger competitors developing similar or superior products.
2. Regulatory hurdles: The process of regulatory approvals for drug candidates involves significant time, costs, and uncertainties. aTyr Pharma may face challenges in obtaining necessary approvals, delaying product launches and revenue generation.
3. Economic factors: Global economic fluctuations, healthcare reforms, or changes in reimbursement policies could impact the affordability and accessibility of aTyr's products, affecting market demand.
aTyr Pharma Eulerpool Fair Value
aTyr Pharma historical P/E ratio, EBIT multiple, and P/S ratio
aTyr Pharma annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
aTyr Pharma shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
aTyr Pharma Earnings Estimates
aTyr Pharma Earnings Estimates
| Date | EPS estimate | Revenue Estimate | Quarterly report |
|---|---|---|---|
| 5/13/2026 | -0.15USD | 0USD | 2026 Q1 |
| 5/5/2026 | -0.15USD | 0USD | 2026 Q1 |
| 3/12/2026 | -0.19USD | 29,141USD | 2025 Q4 |
| 8/11/2025 | -0.19USD | 0USD | 2025 Q2 |
| 11/7/2024 | -0.23USD | 20,400USD | 2024 Q3 |
aTyr Pharma shareholder structure
| % | Name |
|---|---|
13.62452% | |
10.76073% | |
5.45336% | |
4.75053% | |
3.89836% | |
2.51131% | |
2.14111% | |
1.78153% | |
1.71609% | |
1.63302% |
aTyr Pharma Executives and Management Board
Dr. Sanjay Shukla
(53)President, Chief Executive Officer, Director · since 2016
Ms. Jill Broadfoot
(64)Chief Financial Officer
Ms. Nancy Denyes
(57)General Counsel, Corporate Secretary
Mr. Eric Benevich
(59)Independent Director
Mr. Timothy Coughlin
(58)Independent Chairman of the Board
Frequently asked questions about aTyr Pharma
The business model of aTyr Pharma Inc is focused on discovering and developing first-in-class medicines based on its knowledge of tRNA synthetase biology. By leveraging their expertise in this field, aTyr Pharma aims to harness the potential of these proteins to develop innovative therapies for a range of rare and severe immune and tissue-related diseases. With a dedicated team and a strong pipeline of product candidates, aTyr Pharma is actively working towards addressing unmet medical needs and improving patient outcomes in various therapeutic areas.
aTyr Pharma stock
aTyr Pharma Peer Group
aTyr Pharma Ticker
aTyr Pharma FIGI
All fundamentals and in-depth analysis of aTyr Pharma
Our stock analysis for aTyr Pharma Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of aTyr Pharma Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.